Summary of Purpose
To compare ICH patients receiving Recombant Factor VII alpha(rFVIIa) beyond 3 to 4 hours from symptom onset with those treated 0 to 3 hours and control patients receiving standard treatment.Read More →
The following dates are available for this trial. Trial information last updated on 14 January 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Novo Nordisk
Randomized clinical trial based on time from symptom onset.